Healthcare, health insurance and Medicare are hot topics and controversial topics at times too. Developments in this sector naturally impact our well-being and they also have a major effect on the economy and political circles.
To help you understand what is going on and what we expect to happen in the future, our highly-experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest...
Some early signs of how Medicare will handle drug price negotiations: Officials plan to announce the initial group of drugs later this year, the first 10 of 140 drugs for which the Centers for Medicare & Medicaid Services (CMS) will be able to negotiate the price by 2033.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
This will give manufacturers time to prepare for talks, which will start for Medicare Part D drugs in 2026 and 2027.
Among the factors that CMS will consider in valuing a drug:
- Clinical benefits
- The net price of alternatives
- Research costs
- Revenue
- Patent protections and
- Federal funding
The industry is warning about lower investment in certain kinds of drugs, namely small-molecule drugs, which are exempt from negotiations for seven years after approval by the Food and Drug Administration (FDA) vs. 11 years for large-molecule drugs or biologics. Small-molecule drugs are manufactured via chemical synthesis and include things like aspirin and other “medicine cabinet” pharmaceuticals.
This forecast first appeared in The Kiplinger Letter. Since 1923, the Letter has helped millions of business executives and investors profit by providing reliable forecasts on business and the economy, as well as what to expect from Washington. Subscribe or get a free issue of The Kiplinger Letter.
-
Is the EV Tax Credit Going Away? What You Need to KnowTax Credits There's a lot of chatter about the President-elect's plans to eliminate the electric vehicle tax credit. Here's what's happening.
-
Being Nimble Is Key to This Fidelity Bond Fund's OutperformanceThe Fidelity Total Bond ETF has done well over the long term as managers adjust to changing tides.
-
Start-ups Trying to (Profitably) Solve the World’s Hardest ProblemsThe Letter More investors are interested in companies working on breakthrough science to tackle huge societal challenges. The field of deep tech has major tailwinds, too.
-
Will lower mortgage rates bring relief to the housing market?The Kiplinger Letter As mortgage rates slowly come down here's what to expect in the housing market over the next year or so.
-
The Big Questions for AR’s FutureThe Letter As Meta shows off a flashy AR prototype, Microsoft quietly stops supporting its own AR headset. The two companies highlight the promise and peril of AR.
-
China's Economy Faces Darkening OutlookThe Letter What the slowdown in China means for U.S. businesses.
-
Should We Worry About the Slowing U.S. EconomyThe Letter With the labor market cooling off and financial markets turning jittery, just how healthy is the economy right now?
-
Aging in Place Will Be Big Business for Home BuildersThe Kiplinger Letter Many people will be looking to make their homes aging-friendly in the years to come.
-
Kiplinger Special: How Businesses Should Budget for 2025Kiplinger Forecasts From fuel to AI software subscriptions, here's what you can expect to pay next year.
-
Intel Braces for an Even Tougher Road AheadThe Kiplinger Letter Amid a long, costly turnaround, Intel resets expectations again. Its new woes raise questions about U.S. industrial policy and global chip competition.
